Alaunos Therapeutics Ownership
| TCRT Stock | USD 2.78 0.32 13.01% |
Shares in Circulation | First Issued 2000-06-30 | Previous Quarter 1.6 M | Current Value 1.7 M | Avarage Shares Outstanding 2.1 M | Quarterly Volatility 14.2 M |
Alaunos Stock Ownership Analysis
The company has price-to-book ratio of 1.58. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Alaunos Therapeutics recorded a loss per share of 2.47. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 18th of July 2024. Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas. Alaunos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. To find out more about Alaunos Therapeutics contact Holger CPA at 346 355 4099 or learn more at https://www.alaunos.com.Besides selling stocks to institutional investors, Alaunos Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Alaunos Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Alaunos Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Alaunos Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Alaunos Therapeutics Insider Trades History
Roughly 4.0% of Alaunos Therapeutics are currently held by insiders. Unlike Alaunos Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Alaunos Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Alaunos Therapeutics' insider trades
Alaunos Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Alaunos Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Alaunos Therapeutics backward and forwards among themselves. Alaunos Therapeutics' institutional investor refers to the entity that pools money to purchase Alaunos Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Barclays Plc | 2025-06-30 | 100.0 | Royal Bank Of Canada | 2025-03-31 | 100.0 | Federation Des Caisses Desjardins Du Quebec | 2025-06-30 | 86.0 | Bank Of America Corp | 2025-06-30 | 85.0 | Bank Of Oklahoma National Association | 2025-06-30 | 66.0 | Asset Dedication, Llc | 2025-06-30 | 46.0 | Key Financial, Inc. | 2025-06-30 | 24.0 | Newbridge Financial Services Group, Inc. | 2025-06-30 | 24.0 | Signaturefd, Llc | 2025-06-30 | 23.0 | Blackrock Inc | 2025-06-30 | 21.4 K | Vanguard Group Inc | 2025-06-30 | 21 K |
Alaunos Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alaunos Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alaunos Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Alaunos Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Alaunos Therapeutics Outstanding Bonds
Alaunos Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Alaunos Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Alaunos bonds can be classified according to their maturity, which is the date when Alaunos Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US98971DAB64 Corp BondUS98971DAB64 | View | |
| ZOETIS INC 395 Corp BondUS98978VAM54 | View | |
| ZOETIS INC 39 Corp BondUS98978VAN38 | View | |
| ZOETIS INC 3 Corp BondUS98978VAL71 | View | |
| ZOETIS INC Corp BondUS98978VAS25 | View | |
| ZOETIS INC 445 Corp BondUS98978VAP85 | View | |
| ZTS 56 16 NOV 32 Corp BondUS98978VAV53 | View | |
| US98978VAT08 Corp BondUS98978VAT08 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Alaunos Stock Analysis
When running Alaunos Therapeutics' price analysis, check to measure Alaunos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alaunos Therapeutics is operating at the current time. Most of Alaunos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alaunos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alaunos Therapeutics' price. Additionally, you may evaluate how the addition of Alaunos Therapeutics to your portfolios can decrease your overall portfolio volatility.